Kymera Therapeutics, Inc.
NASDAQ:KYMR
46.44 (USD) • At close September 18, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Omzet
| 78.592 | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
| Kosten van de omzet
| 3.565 | 2.977 | 2.397 | 62.105 | 0.825 | 0.205 |
| Brutowinst
| 75.027 | 43.849 | 70.435 | -28.071 | 2.109 | -0.205 |
| Brutowinstmarge
| 0.955 | 0.936 | 0.967 | -0.825 | 0.719 | 0 |
| Onderzoek- en ontwikkelingskosten
| 189.081 | 164.248 | 137.017 | 62.105 | 37.158 | 17.679 |
| Algemene en administratieve kosten
| 55.041 | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 55.041 | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
| Overige kosten
| 0 | 0 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 244.122 | 208.082 | 173.362 | 80.338 | 45.139 | 21.451 |
| Bedrijfsresultaat
| -165.53 | -161.256 | -100.53 | -46.304 | -42.205 | -21.451 |
| Bedrijfsresultaat ratio
| -2.106 | -3.444 | -1.38 | -1.361 | -14.385 | 0 |
| Totaal overige inkomsten en kosten netto
| 18.568 | 6.448 | 0.313 | 0.711 | 0.959 | -0.016 |
| Inkomen voor belasting
| -146.962 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Inkomen voor belasting ratio
| -1.87 | -3.306 | -1.376 | -1.34 | -14.058 | 0 |
| Belastingkosten
| 18.764 | -2.977 | -2.222 | -1.648 | 0.046 | 0.044 |
| Nettowinst
| -146.962 | -151.831 | -97.995 | -43.945 | -41.292 | -21.467 |
| Nettowinstmarge
| -1.87 | -3.242 | -1.345 | -1.291 | -14.074 | 0 |
| WPA (Winst Per Aandeel)
| -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -1.07 |
| Verwaterde WPA
| -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -1.07 |
| EBITDA
| -143.201 | -154.632 | -100.042 | -45.478 | -40.375 | -21.246 |
| EBITDA ratio
| -1.822 | -3.302 | -1.374 | -1.336 | -13.761 | 0 |